CD274 and neoplasm: The study IMpower 010 (20) addressed some of the unmet needs for adjuvant treatment oncodriver-negative tumors, adding immunotherapy in the plethora of new approvals in the early setting of NSCLC for patients expressing PD-L1 >1% on tumor cells (20).